Pentagastrin

CHEMBL1328 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
767.9 g/mol
LogP
1.5
Phase
4

A synthetic pentapeptide analogue of gastrin used diagnostically to stimulate gastric acid secretion and test the function of parietal cells, helping diagnose conditions such as pernicious anemia and Zollinger-Ellison syndrome. It is also used to stimulate calcitonin secretion as a provocative test for medullary thyroid carcinoma.

Masse moléculaire

767,9000 g/mol

LogP

1,50

TPSA

276,00 Ų

Règle des 5 de Lipinski

Non conforme

Aires thérapeutiques

Mécanisme d'action

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CSCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)CCNC(=O)OC(C)(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

InChI

InChI=1S/C37H49N7O9S/c1-37(2,3)53-36(52)39-16-14-30(45)41-28(19-23-21-40-25-13-9-8-12-24(23)25)34(50)42-26(15-17-54-4)33(49)44-29(20-31(46)47)35(51)43-27(32(38)48)18-22-10-6-5-7-11-22/h5-13,21,26-29,40H,14-20H2,1-4H3,(H2,38,48)(H,39,52)(H,41,45)(H,42,50)(H,43,51)(H,44,49)(H,46,47)/t26-,27-,28-,29-/m0/s1

Molecular Formula

C37H49N7O9S

HBD / HBA

8 / 10

Liaisons Rotatives

22

Atomes Lourds

54

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A synthetic pentapeptide analogue of gastrin used diagnostically to stimulate gastric acid secretion and test the function of parietal cells, helping diagnose conditions such as pernicious anemia and Zollinger-Ellison syndrome. It is also used to stimulate calcitonin secretion as a provocative test for medullary thyroid carcinoma.

Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.

Yes, Pentagastrin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1328. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 9853654. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.